Role of IL-2 in cancer immunotherapy

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Jiang, Tao ^a   Zhou, Caicun ^a   Ren, Shengxiang ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer; combined therapy; cytokine; immunotherapy; interleukin 2

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMMUNOCYTOKINE; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; VINBLASTINE;

CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL THERAPY; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG MEGADOSE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE SYSTEM; KIDNEY METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

EID: 84973098657     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1163462     Document Type: Review

References (99)

1. D.A.Morgan, F.W.Ruscetti, R.Gallo. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193:1007-8; PMID:181845; 10.1126/science.181845
2. T.R.Malek. The biology of interleukin-2. Annu Rev Immunol 2008; 26:453-79; PMID:18062768; 10.1146/annurev.immunol.26.021607.090357
3. X.Wang, P.Lupardus, S.L.Laporte, K.C.Garcia. Structural biology of shared cytokine receptors. Annu Rev Immunol 2009; 27:29-60; PMID:18817510; 10.1146/annurev.immunol.24.021605.090616
4. W.Liao, J.X.Lin, W.J.Leonard. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13-25; PMID:23352221; 10.1016/j.immuni.2013.01.004
5. D.Skrombolas, J.G.Frelinger. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol 2014; 10:207-17; PMID:24410537; 10.1586/1744666X.2014.875856
6. X.Paliard, R.de Waal Malefijt, H.Yssel, D.Blanchard, I.Chretien, J.Abrams, J.de Vries, H.Spits. Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones. J Immunol 1988; 141:849-55; PMID:2969394; 10.0022-l767/88/1413-084902.00
7. W.J.Leonard. Cytokines and immunodeficiency diseases. Nat Rev Immunol 2001; 1:200-8; PMID:11905829; 10.1038/35105066
8. M.A.Yui, L.L.Sharp, W.L.Havran, E.V.Rothenberg. Preferential activation of an IL-2 regulatory sequence transgene in TCR gamma delta and NKT cells: subset-specific differences in IL-2 regulation. J Immunol 2004; 172:4691-9; PMID:15067044; 10.4049/jimmunol.172.8.4691
9. W.E.Paul, J.Zhu. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010; 10:225-35; PMID:20336151; 10.1038/nri2735
10. S.J.Szabo, B.M.Sullivan, S.L.Peng, L.H.Glimcher. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003; 21:713-58; PMID:12500979; 10.1146/annurev.immunol.21.120601.140942
11. D.R.Littman, A.Y.Rudensky. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140:845-58; PMID:20303875; 10.1016/j.cell.2010.02.021
12. A.Y.Rudensky. Regulatory T cells and Foxp3. Immunol Rev 2011; 241:260-8; PMID:21488902; 10.1111/j.1600-065X.2011.01018.x
13. W.J.Leonard, M.Kronke, N.J.Peffer, J.M.Depper, W.C.Greene. Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sci U S A 1985; 82:6281-5; PMID:3929255; 10.1073/pnas.82.18.6281
14. M.Brisslert, M.Bokarewa, P.Larsson, K.Wing, L.V.Collins, A.Tarkowski. Phenotypic and functional characterization of human CD25+ B cells. Immunology 2006; 117:548-57; PMID:16556269; 10.1111/j.1365-2567.2006.02331.x
15. V.Kronin, D.Vremec, K.Shortman. Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function? Int Immunol 1998; 10:237-40; PMID:9533452; 10.1093/intimm/10.2.237
16. C.Krieg, S.Letourneau, G.Pantaleo, O.Boyman. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010; 107:11906-11; PMID:20547866; 10.1073/pnas.1002569107
17. E.M.Shevach. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30:636-45; PMID:19464986; 10.1016/j.immuni.2009.04.010
18. G.C.Sim, L.Radvanyi. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev 2014; 25:377-90; PMID:25200249; 10.1016/j.cytogfr.2014.07.018
19. D.Cosman. The hematopoietin receptor superfamily. Cytokine 1993; 5:95-106; PMID:8392875; 10.1016/1043-4666(93)90047-9
20. H.P.Kim, J.Imbert, W.J.Leonard. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 2006; 17:349-66; PMID:16911870; 10.1016/j.cytogfr.2006.07.003
21. B.H.Nelson, D.M.Willerford. Biology of the interleukin-2 receptor. Adv Immunol 1998; 70:1-81; PMID:9755337; 10.1016/S0065-2776(08)60386-7
22. L.Bani, D.David, J.L.Moreau, A.Cayota, T.Nakarai, J.Ritz, J.Theze. Expression of the IL-2 receptor gamma subunit in resting human CD4 T lymphocytes: mRNA is constitutively transcribed and the protein stored as an intracellular component. Int Immunol 1997; 9:573-80; PMID:9138018; 10.1093/intimm/9.4.573
23. M.Rickert, X.Wang, M.J.Boulanger, N.Goriatcheva, K.C.Garcia. The structure of interleukin-2 complexed with its alpha receptor. Science. 2005; 308:1477-80; PMID:15933202; 10.1126/science.1109745
24. Y.Minami, T.Kono, T.Miyazaki, T.Taniguchi. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11:245-68; PMID:8476561; 10.1146/annurev.iy.11.040193.001333
25. K.A.Smith. Interleukin-2: inception, impact, and implications. Science 1988; 240:1169-76; PMID:3131876; 10.1126/science.3131876
26. T.Waldmann, Y.Tagaya, R.Bamford. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998; 16:205-26; PMID:9505189; 10.3109/08830189809042995
27. S.A.Rosenberg, M.T.Lotze, L.M.Muul, S.Leitman, A.E.Chang, S.E.Ettinghausen, Y.L.Matory, J.M.Skibber, E.Shiloni, J.T.Vetto et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-92; PMID:3903508; 10.1056/NEJM198512053132327
28. S.A.Rosenberg. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-8; PMID:24907378; 10.4049/jimmunol.1490019
29. M.B.Atkins, J.Sparano, R.I.Fisher, G.R.Weiss, K.A.Margolin, K.I.Fink, L.Rubinstein, A.Louie, J.W.Mier, R.Gucalp et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993; 11:661-70; PMID:8478661; 10.1146/annurev.iy.11.040193.001333
30. J.I.Clark, T.M.Kuzel, T.M.Lestingi, S.G.Fisher, P.Sorokin, B.Martone, M.Viola, J.A.Sosman. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. Ann Oncol 2002; 13:606-13; PMID:12056712; 10.1093/annonc/mdf105
31. J.P.Dutcher, R.I.Fisher, G.Weiss, F.Aronson, K.Margolin, A.Louie, J.Mier, G.Caliendo, J.A.Sosman, J.R.Eckardt et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997; 3:157-62; PMID:9161781
32. D.F.McDermott, M.M.Regan, J.I.Clark, L.E.Flaherty, G.R.Weiss, T.F.Logan, J.M.Kirkwood, M.S.Gordon, J.A.Sosman, M.S.Ernstoff et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-41; PMID:15625368; 10.1200/JCO.2005.03.206
33. S.Negrier, B.Escudier, C.Lasset, J.Y.Douillard, J.Savary, C.Chevreau, A.Ravaud, A.Mercatello, J.Peny, M.Mousseau et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-8; PMID:9562581; 10.1056/NEJM199804303381805
34. J.C.Yang, R.M.Sherry, S.M.Steinberg, S.L.Topalian, D.J.Schwartzentruber, P.Hwu, C.A.Seipp, L.Rogers-Freezer, K.E.Morton, D.E.White et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-32; PMID:12915604; 10.1200/JCO.2003.02.122
35. A.Mazumder, E.A.Grimm, H.Z.Zhang, S.A.Rosenberg. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res 1982; 42:913-8; PMID:7059990; 10.0008-5472/82/0042-000002.00
36. E.A.Grimm, A.Mazumder, H.Z.Zhang, S.A.Rosenberg. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823-41; PMID:6176669; 10.1084/jem.155.6.1823
37. S.A.Rosenberg, M.T.Lotze, J.C.Yang, P.M.Aebersold, W.M.Linehan, C.A.Seipp, D.E.White. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474-84; discussion 484-5; PMID:2679456; 10.1097/00000658-198910000-00008
38. M.E.Dudley, J.R.Wunderlich, J.C.Yang, R.M.Sherry, S.L.Topalian, N.P.Restifo, R.E.Royal, U.Kammula, D.E.White, S.A.Mavroukakis et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-57; PMID:15800326; 10.1200/JCO.2005.00.240
39. M.E.Dudley, J.C.Yang, R.Sherry, M.S.Hughes, R.Royal, U.Kammula, P.F.Robbins, J.Huang, D.E.Citrin, S.F.Leitman et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; 10.1200/JCO.2008.16.5449
40. N.P.Restifo, M.E.Dudley, S.A.Rosenberg. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; 10.1038/nri3191
41. S.A.Rosenberg, N.P.Restifo, J.C.Yang, R.A.Morgan, M.E.Dudley. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; 10.1038/nrc2355
42. Y.Li, S.Liu, J.Hernandez, L.Vence, P.Hwu, L.Radvanyi. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 2010; 184:452-65; PMID:19949105; 10.4049/jimmunol.0901101
43. M.B.Atkins. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006; 12:2353s-8s; PMID:16609058; 10.1158/1078-0432.CCR-05-2503
44. U.Keilholz, S.H.Goey, C.J.Punt, T.M.Proebstle, R.Salzmann, C.Scheibenbogen, D.Schadendorf, D.Lienard, A.Enk, R.Dummer et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997; 15:2579-88; PMID:9215828; 10.0732-183X/97/1507-00033.00/0
45. O.Eton, S.S.Legha, A.Y.Bedikian, J.J.Lee, A.C.Buzaid, C.Hodges, S.E.Ring, N.E.Papadopoulos, C.Plager, M.J.East et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-52; PMID:11956264; 10.1200/JCO.2002.07.044
46. S.A.Rosenberg, J.C.Yang, D.J.Schwartzentruber, P.Hwu, F.M.Marincola, S.L.Topalian, C.A.Seipp, J.H.Einhorn, D.E.White, S.M.Steinberg. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968-75; PMID:10071291
47. U.Keilholz, C.J.Punt, M.Gore, W.Kruit, P.Patel, D.Lienard, J.Thomas, T.M.Proebstle, A.Schmittel, D.Schadendorf et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23:6747-55; PMID:16170182; 10.1200/JCO.2005.03.202
48. R.Ridolfi, V.Chiarion-Sileni, M.Guida, A.Romanini, R.Labianca, A.Freschi, G.Lo Re, R.Nortilli, S.Brugnara, P.Vitali et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002; 20:1600-7; PMID:11896110; 10.1200/JCO.20.6.1600
49. E.Bajetta, M.Del Vecchio, P.Nova, A.Fusi, A.Daponte, M.R.Sertoli, P.Queirolo, P.Taveggia, M.G.Bernengo, S.S.Legha et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006; 17:571-7; PMID:16469753; 10.1093/annonc/mdl007
50. M.B.Atkins, J.Hsu, S.Lee, G.I.Cohen, L.E.Flaherty, J.A.Sosman, V.K.Sondak, J.M.Kirkwood, Eastern Cooperative Oncology G. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748-54; PMID:19001327; 10.1200/JCO.2008.17.5448
51. A.D.Sasse, E.C.Sasse, L.G.Clark, L.Ulloa, O.A.Clark. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; CD005413; PMID:17253556; 10.1002/14651858.CD005413.pub2
52. N.J.Ives, R.L.Stowe, P.Lorigan, K.Wheatley. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25:5426-34; PMID:18048825; 10.1200/JCO.2007.12.0253
53. K.L.Redmond, A.Papafili, M.Lawler, S.Van Schaeybroeck. Overcoming Resistance to Targeted Therapies in Cancer. Semin Oncol. 2015; 42:896-908; PMID:26615134; 10.1053/j.seminoncol.2015.09.028
54. P.A.Janne, J.C.Yang, D.W.Kim, D.Planchard, Y.Ohe, S.S.Ramalingam, M.J.Ahn, S.W.Kim, W.C.Su, L.Horn et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372:1689-99; PMID:25923549; 10.1056/NEJMoa1411817
55. C.S.Tan, D.Gilligan, S.Pacey. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol 2015; 16:e447-59; PMID:26370354; 10.1016/S1470-2045(15)00246-6
56. F.De Vita, G.Turitto, M.di Grazia, A.Frattolillo, G.Catalano. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer. Tumori 1998; 84:33-8; PMID:9619711
57. Y.M.Chen, W.K.Yang, J.Whang-Peng, W.Y.Tsai, Y.M.Hung, D.M.Yang, W.C.Lin, R.P.Perng, C.C.Ting. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J Immunother 1997; 20:354-64; PMID:9336742; 10.1097/00002371-199709000-00004
58. K.Umekawa, T.Kimura, S.Kudoh, T.Suzumura, T.Oka, M.Nagata, S.Mitsuoka, K.Matsuura, T.Nakai, N.Yoshimura et al. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. BMC Res Notes 2013; 6:139; PMID:23566546; 10.1186/1756-0500-6-139
59. N.Yamamoto, M.Honma, H.Suzuki. Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders. Mol Pharmacol 2011; 80:466-75; PMID:21606217; 10.1124/mol.110.070862
60. M.Bersanelli, S.Buti, R.Camisa, M.Brighenti, S.Lazzarelli, G.Mazza, R.Passalacqua. Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy. Cancers (Basel) 2014; 6:2035-48; PMID:25271833; 10.3390/cancers6042035
61. E.T.Lam, M.K.Wong, N.Agarwal, B.G.Redman, T.Logan, D.Gao, T.W.Flaig, K.Lewis, J.Poust, P.Monk et al. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother 2014; 37:360-5; PMID:25075565; 10.1097/CJI.0000000000000044
62. W.W.Overwijk, M.R.Theoret, N.P.Restifo. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am 2000; 6(Suppl 1):S76-80; PMID:10685664
63. F.O.Smith, S.G.Downey, J.A.Klapper, J.C.Yang, R.M.Sherry, R.E.Royal, U.S.Kammula, M.S.Hughes, N.P.Restifo, C.L.Levy et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14:5610-8; PMID:18765555; 10.1158/1078-0432.CCR-08-0116
64. D.J.Schwartzentruber, D.H.Lawson, J.M.Richards, R.M.Conry, D.M.Miller, J.Treisman, F.Gailani, L.Riley, K.Conlon, B.Pockaj et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364:2119-27; PMID:21631324; 10.1056/NEJMoa1012863
65. J.F.Brunet, F.Denizot, M.F.Luciani, M.Roux-Dosseto, M.Suzan, M.G.Mattei, P.Golstein. A new member of the immunoglobulin superfamily–CTLA-4. Nature 1987; 328:267-70; PMID:3496540; 10.1038/328267a0
66. K.Adachi, K.Tamada. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci 2015; 106:945-50; PMID:25981182; 10.1111/cas.12695
67. J.R.Brahmer. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2014; 41:126-32; PMID:24565586; 10.1053/j.seminoncol.2013.12.014
68. A.van Elsas, A.A.Hurwitz, J.P.Allison. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66; PMID:10430624; 10.1084/jem.190.3.355
69. D.R.Leach, M.F.Krummel, J.P.Allison. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6; PMID:8596936; 10.1126/science.271.5256.1734
70. A.A.Hurwitz, B.A.Foster, E.D.Kwon, T.Truong, E.M.Choi, N.M.Greenberg, M.B.Burg, J.P.Allison. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60:2444-8; PMID:10811122
71. A.V.Maker, G.Q.Phan, P.Attia, J.C.Yang, R.M.Sherry, S.L.Topalian, U.S.Kammula, R.E.Royal, L.R.Haworth, C.Levy et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005-16; PMID:16283570; 10.1245/ASO.2005.03.536
72. D.Hannani, M.Vetizou, D.Enot, S.Rusakiewicz, N.Chaput, D.Klatzmann, M.Desbois, N.Jacquelot, N.Vimond, S.Chouaib et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015; 25:208-24; PMID:25582080; 10.1038/cr.2015.3
73. M.Ahmadzadeh, S.A.Rosenberg. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107:2409-14; PMID:16304057; 10.1182/blood-2005-06-2399
74. A.Berntsen, M.K.Brimnes, P.thor Straten, I.M.Svane. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother 2010; 33:425-34; PMID:20386464; 10.1097/CJI.0b013e3181cd870f
75. G.C.Sim, N.Martin-Orozco, L.Jin, Y.Yang, S.Wu, E.Washington, D.Sanders, C.Lacey, Y.Wang, L.Vence, P.Hwu, L.Radvanyi. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014; 124:99-110; PMID:24292706; 10.1172/JCI46266
76. X.Yao, M.Ahmadzadeh, Y.C.Lu, D.J.Liewehr, M.E.Dudley, F.Liu, D.S.Schrump, S.M.Steinberg, S.A.Rosenberg, P.F.Robbins. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012; 119:5688-96; PMID:22555974; 10.1182/blood-2011-10-386482
77. M.K.Gately, T.D.Anderson, T.J.Hayes. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J Immunol 1988; 141:189-200; PMID:3259967; 10.0022-l767/88/1411-018902.0
78. D.J.Peace, M.A.Cheever. Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 1989; 169:161-73; PMID:2783332; 10.1084/jem.169.1.161
79. E.Assier, V.Jullien, J.Lefort, J.L.Moreau, J.P.Di Santo, B.B.Vargaftig, J.R.Lapa e Silva, J.Theze. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J Immunol 2004; 172:7661-8; PMID:15187148; 10.4049/jimmunol.172.12.7661
80. A.L.Epstein, F.M.Chen, C.R.Taylor. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988; 48:5842-8; PMID:3048650
81. D.C.Gallagher, R.S.Bhatt, S.M.Parikh, P.Patel, V.Seery, D.F.McDermott, M.B.Atkins, V.P.Sukhatme. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res 2007; 13:2115-20; PMID:17404094; 10.1158/1078-0432.CCR-06-2509
82. W.E.Samlowski, M.Kondapaneni, S.Tharkar, J.R.McGregor, V.E.Laubach, D.Salvemini. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J Immunother 2011; 34:419-27; PMID:21577143; 10.1097/CJI.0b013e31821dcb50
83. B.M.Rao, A.T.Girvin, T.Ciardelli, D.A.Lauffenburger, K.D.Wittrup. Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng 2003; 16:1081-7; PMID:14983090; 10.1093/protein/gzg111
84. B.M.Rao, I.Driver, D.A.Lauffenburger, K.D.Wittrup. Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol Pharmacol 2004; 66:864-9; PMID:15385640; 10.1124/mol.66.4
85. A.B.Shanafelt, Y.Lin, M.C.Shanafelt, C.P.Forte, N.Dubois-Stringfellow, C.Carter, J.A.Gibbons, S.L.Cheng, K.A.Delaria, R.Fleischer et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol. 2000; 18:1197-202; PMID:11062441; 10.1038/81199
86. K.Margolin, M.B.Atkins, J.P.Dutcher, M.S.Ernstoff, J.W.Smith, 2nd, J.I.Clark, J.Baar, J.Sosman, J.Weber, C.Lathia et al. Phase I trial of BAY 50–4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 2007; 13:3312-9; PMID:17545537; 10.1158/1078-0432.CCR-06-1341
87. K.M.Heaton, G.Ju, E.A.Grimm. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res 1993; 53:2597-602; PMID:8495422
88. K.M.Heaton, E.A.Grimm. Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2. Hum Immunol 1995; 42:274-80; PMID:7759316; 10.1016/0198-8859(94)00106-Z
89. A.M.Levin, D.L.Bates, A.M.Ring, C.Krieg, J.T.Lin, L.Su, I.Moraga, M.E.Raeber, G.R.Bowman, P.Novick et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 2012; 484:529-33; PMID:22446627; 10.1038/nature10975
90. D.Schrama, R.A.Reisfeld, J.C.Becker. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5:147-59; PMID:16424916; 10.1038/nrd1957
91. T.List, D.Neri. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 2013; 5:29-45; PMID:23990735; 10.2147/CPAA.S49231
92. H.Sabzevari, S.D.Gillies, B.M.Mueller, J.D.Pancook, R.A.Reisfeld. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A 1994; 91:9626-30; PMID:7937818; 10.1073/pnas.91.20.9626
93. B.Carnemolla, L.Borsi, E.Balza, P.Castellani, R.Meazza, A.Berndt, S.Ferrini, H.Kosmehl, D.Neri, L.Zardi. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002; 99:1659-65; PMID:11861281; 10.1182/blood.V99.5.1659
94. C.Schliemann, A.Palumbo, K.Zuberbuhler, A.Villa, M.Kaspar, E.Trachsel, W.Klapper, H.D.Menssen, D.Neri. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009; 113:2275-83; PMID:19005180; 10.1182/blood-2008-05-160747
95. K.`Wagner, P.Schulz, A.Scholz, B.Wiedenmann, A.Menrad. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 2008; 14:4951-60; PMID:18676770; 10.1158/1078-0432.CCR-08-0157
96. K.L.Osenga, J.A.Hank, M.R.Albertini, J.Gan, A.G.Sternberg, J.Eickhoff, R.C.Seeger, K.K.Matthay, C.P.Reynolds, C.Twist et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006; 12:1750-9; PMID:16551859; 10.1158/1078-0432.CCR-05-2000
97. Y.J.Ko, G.J.Bubley, R.Weber, C.Redfern, D.P.Gold, L.Finke, A.Kovar, T.Dahl, S.D.Gillies. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother 2004; 27:232-9; PMID:15076141; 10.1097/00002371-200405000-00008
98. J.Puskas, D.Skrombolas, A.Sedlacek, E.Lord, M.Sullivan, J.Frelinger. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. Immunology 2011; 133:206-20; PMID:21426339; 10.1111/j.1365-2567.2011.03428.x
99. F.Deknuydt, G.Bioley, D.Valmori, M.Ayyoub. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009; 131:298-307; PMID:19211307; 10.1016/j.clim.2008.12.008